CVC Credit has priced Apidos LIII, a new $475m (£356m) collateralised loan obligation, representing the third new CLO priced globally by CVC Credit this year.
Apidos LIII has a five year reinvestment period and a two year non-call period, backed by a portfolio of senior secured assets.
Read more: CVC Credit prices first CLO deal of 2025
The three CLOs priced by CVC Credit this year have an aggregate value of $1.4bn.
“Apidos LIII was very well received from our global investors during very challenging market conditions, which reflects CVC’s proven track record, and the strength of our relationships with global investors across the capital stack,” said CVC credit partner and global head of CLO origination Cary Ho.
“We are happy with the structure and the quality of assets we have been able to purchase during the early stages of this deal.”
Read more: CVC eyes acquisition of US private credit giant Golub Capital – reports
Kevin O’Meara, partner and global co-head of performing credit at CVC Credit, said: “We believe the volatility over the last couple of months has and will continue to create attractive investment options for our investors and we will strive to capitalise on these opportunities.”
Read more: CVC beats profit expectations as AUM reaches €200bn
